I-Mab Biopharma Co., Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From I-Mab Biopharma Co., Ltd
Facing a increasingly competitive environment and tense bilateral relationship, US biotechs must innovate and differentiate while protecting their innovations in China, say panelists at the BIO annual conference.
Plus deals involving I-Mab/Complix, Lupin/Endoceutics, Genome & Co/Pfizer/Merck KGaA, Genome & Co/Debiopharm, Exelixis/WuXi, Intas/Foresee, Wugen/Alpha Biosciences
Plus deals involving Scynexis/Hansoh, Cend/Qilu, Apollomics/Edison, Apollomics/Iterion, Apollomics/Nuance, Aerami/Chance, Antibe/Nuance, Ildong/Arbormed
Top executives from three high-flying Chinese biotechs, all of which have gone public on Nasdaq and in Hong Kong, offered lessons learned and looked forward to what’s ahead in a panel session at the recent JPM conference.
- Large Molecule
- Other Names / Subsidiaries
- Tasgen Biotech
- Third Venture Biopharma